中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值是接受放化疗的局部晚期胰腺癌患者的预后因素。

The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.

机构信息

Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Gut Liver. 2018 May 15;12(3):342-352. doi: 10.5009/gnl17216.

BACKGROUND/AIMS: We investigated whether inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) independently and in combination would be significant prognostic factors for survival in patients with locally advanced pancreatic cancer.

METHODS

A total of 497 patients with locally advanced pancreatic cancer who received neoadjuvant or definitive chemoradiotherapy from 2005 to 2015 were evaluated. We divided the patients into groups according to the median values of NLR and PLR: NLR＜1.89 (n=156), NLR≥1.89 (n=341), PLR ＜149 (n=248) and PLR ≥149 (n=249).

RESULTS

For NLR ＜1.89 and ≥1.89 groups, respectively, the 1-year overall survival (OS) rates were 73.2% and 60.8% (p＜0.001) and 1-year progression-free survival (PFS) rates were 43.9% and 31.3% (p＜0.001). For PLR ＜149 and ≥149 groups, respectively, the 1-year OS rates were 68.1% and 61.3% (p=0.029) and 1-year PFS rates were 37.9% and 32.5% (p=0.027). Patients with both high NLR and high PLR showed the worst OS and PFS rates compared with those with both lower NLR and lower PLR.

CONCLUSIONS

Elevated pretreatment NLR and PLR independently and in combination significantly predicted poor OS and PFS.

背景/目的：我们研究了炎症标志物，如中性粒细胞-淋巴细胞比值（NLR）和血小板-淋巴细胞比值（PLR），在单独和联合使用时是否为局部晚期胰腺癌患者生存的重要预后因素。

方法

对 2005 年至 2015 年间接受新辅助或根治性放化疗的 497 例局部晚期胰腺癌患者进行评估。我们根据 NLR 和 PLR 的中位数将患者分为两组：NLR＜1.89（n=156）、NLR≥1.89（n=341）、PLR＜149（n=248）和 PLR≥149（n=249）。

结果

对于 NLR＜1.89 和 NLR≥1.89 组，1 年总生存率（OS）分别为 73.2%和 60.8%（p＜0.001），1 年无进展生存率（PFS）分别为 43.9%和 31.3%（p＜0.001）。对于 PLR＜149 和 PLR≥149 组，1 年 OS 率分别为 68.1%和 61.3%（p=0.029），1 年 PFS 率分别为 37.9%和 32.5%（p=0.027）。与 NLR 和 PLR 均较低的患者相比，同时具有高 NLR 和高 PLR 的患者的 OS 和 PFS 最差。